Moleculin Biotech Stock Alpha and Beta Analysis
| MBRX Stock | USD 1.51 0.04 2.58% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Moleculin Biotech. It also helps investors analyze the systematic and unsystematic risks associated with investing in Moleculin Biotech over a specified time horizon. Remember, high Moleculin Biotech's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Moleculin Biotech's market risk premium analysis include:
Beta 1.4 | Alpha (0.73) | Risk 6.63 | Sharpe Ratio (0.13) | Expected Return (0.87) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Moleculin |
Moleculin Biotech Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Moleculin Biotech market risk premium is the additional return an investor will receive from holding Moleculin Biotech long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Moleculin Biotech. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Moleculin Biotech's performance over market.| α | -0.73 | β | 1.40 |
Moleculin Biotech expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Moleculin Biotech's Buy-and-hold return. Our buy-and-hold chart shows how Moleculin Biotech performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Moleculin Biotech Market Price Analysis
Market price analysis indicators help investors to evaluate how Moleculin Biotech stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Moleculin Biotech shares will generate the highest return on investment. By understating and applying Moleculin Biotech stock market price indicators, traders can identify Moleculin Biotech position entry and exit signals to maximize returns.
Moleculin Biotech Return and Market Media
The median price of Moleculin Biotech for the period between Thu, Nov 7, 2024 and Wed, Feb 5, 2025 is 2.32 with a coefficient of variation of 20.05. The daily time series for the period is distributed with a sample standard deviation of 0.44, arithmetic mean of 2.19, and mean deviation of 0.41. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast | 11/05/2024 |
2 | Moleculin Biotech to Report Financial Results for Q3 2024 Houston, TXMoleculin Biotech, Inc. announced in an 8-K filing today that it will disclose its financia... | 11/08/2024 |
3 | Earnings call Moleculin Biotech optimistic on Annamycins trial | 11/12/2024 |
4 | Armistice Capital, LLC Expands Portfolio with Moleculin Biotech Inc Acquisition | 11/15/2024 |
5 | Acquisition by Donald Picker of 65000 shares of Moleculin Biotech subject to Rule 16b-3 | 11/27/2024 |
6 | Moleculin Announces Online Publication of Preclinical Data Demonstrating Significant Activity of Annamycin in Venetoclax Resistant AML Model | 12/11/2024 |
7 | Disposition of 56250 shares by Walter Klemp of Moleculin Biotech subject to Rule 16b-3 | 12/12/2024 |
8 | Moleculin Biotech stock hits 52-week low at 2.11 - Investing.com | 12/16/2024 |
9 | Acquisition by Donald Picker of 16167 shares of Moleculin Biotech subject to Rule 16b-3 | 12/24/2024 |
10 | Moleculin Highlights Development Progress of Annamycin, Phase 2 Data Outperforms Billion-Dollar Assets in AML, Phase 3 Data Readouts in 2025 2026 | 01/08/2025 |
11 | Acquisition by Foster Jonathan P. of 162667 shares of Moleculin Biotech subject to Rule 16b-3 | 01/22/2025 |
12 | Moleculin Biotech Shares Updates on MIRACLE Trial - TipRanks | 01/27/2025 |
About Moleculin Biotech Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Moleculin or other stocks. Alpha measures the amount that position in Moleculin Biotech has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2024 | 2025 (projected) | Net Debt To EBITDA | 1.4 | 0.7 | 0.94 | Intangibles To Total Assets | 0.19 | 0.34 | 0.45 |
Moleculin Biotech Upcoming Company Events
As portrayed in its financial statements, the presentation of Moleculin Biotech's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Moleculin Biotech's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Moleculin Biotech's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Moleculin Biotech. Please utilize our Beneish M Score to check the likelihood of Moleculin Biotech's management manipulating its earnings.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Moleculin Biotech
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Moleculin Stock Analysis
When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.